Newland Pharmaceutical Co., Ltd. (SHE:301277)
China
· Delayed Price · Currency is CNY 11.53
0.00 (0.00%)
Apr 29, 2026, 4:00 PM EDT
Newland Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2019 |
| Net Income | 100.78 | 121.25 | 173.63 | 158.98 | 132.3 | 114.98 | Upgrade
|
| Depreciation & Amortization | 55.07 | 55.07 | 37.84 | 31.08 | 24.24 | 20.86 | Upgrade
|
| Other Amortization | 2.47 | 2.47 | 2.23 | 1.54 | 0.16 | - | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | -0.07 | 0.44 | 0.21 | Upgrade
|
| Asset Writedown & Restructuring Costs | 1.49 | 1.49 | 2.62 | 1.46 | 0.32 | 0.11 | Upgrade
|
| Loss (Gain) From Sale of Investments | -10.44 | -10.44 | -13.95 | -17.6 | -1.52 | -0.17 | Upgrade
|
| Provision & Write-off of Bad Debts | -0.87 | -0.87 | 2.27 | -3.6 | 2.23 | 11.14 | Upgrade
|
| Other Operating Activities | -26.92 | 8.63 | 5.05 | -0.65 | 6.29 | 6.54 | Upgrade
|
| Change in Accounts Receivable | 66.03 | 66.03 | -82.3 | 117.51 | -146.8 | -99.16 | Upgrade
|
| Change in Inventory | -32.92 | -32.92 | -18.25 | 21.6 | 25.05 | -29.15 | Upgrade
|
| Change in Accounts Payable | -93.4 | -93.4 | 17.32 | -54.7 | 28.45 | 20 | Upgrade
|
| Change in Other Net Operating Assets | -1.6 | -1.6 | 0.3 | -0.48 | 5.28 | 3.9 | Upgrade
|
| Operating Cash Flow | 60.92 | 116.94 | 126.76 | 259.46 | 82.85 | 49.08 | Upgrade
|
| Operating Cash Flow Growth | -54.57% | -7.75% | -51.14% | 213.19% | 68.80% | 2.55% | Upgrade
|
| Capital Expenditures | -63.77 | -101.38 | -110.79 | -96.51 | -74.34 | -25.4 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.04 | 0.06 | 0.14 | 0.54 | 0.04 | 0.06 | Upgrade
|
| Investment in Securities | -92.55 | -13.95 | 78.28 | 129.46 | -691.5 | -8.5 | Upgrade
|
| Other Investing Activities | -1.72 | - | - | - | 0.33 | 0 | Upgrade
|
| Investing Cash Flow | -158 | -115.28 | -32.36 | 33.48 | -765.47 | -33.83 | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | 89.09 | 118.46 | Upgrade
|
| Total Debt Issued | - | - | - | - | 89.09 | 118.46 | Upgrade
|
| Long-Term Debt Repaid | - | -1.8 | -3.25 | -2.75 | -203.05 | -100 | Upgrade
|
| Total Debt Repaid | -1.8 | -1.8 | -3.25 | -2.75 | -203.05 | -100 | Upgrade
|
| Net Debt Issued (Repaid) | -1.8 | -1.8 | -3.25 | -2.75 | -113.96 | 18.46 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 838.57 | 4 | Upgrade
|
| Common Dividends Paid | -112.02 | -112.02 | -80.02 | -66.68 | -6.77 | -36.7 | Upgrade
|
| Other Financing Activities | 0.81 | - | - | - | -19.09 | -6.94 | Upgrade
|
| Financing Cash Flow | -113.01 | -113.82 | -83.26 | -69.43 | 698.74 | -21.19 | Upgrade
|
| Net Cash Flow | -210.09 | -112.16 | 11.14 | 223.51 | 16.12 | -5.94 | Upgrade
|
| Free Cash Flow | -2.85 | 15.55 | 15.97 | 162.94 | 8.5 | 23.68 | Upgrade
|
| Free Cash Flow Growth | - | -2.63% | -90.20% | 1816.39% | -64.10% | -23.36% | Upgrade
|
| Free Cash Flow Margin | -0.43% | 2.31% | 2.20% | 25.01% | 1.35% | 4.61% | Upgrade
|
| Free Cash Flow Per Share | -0.01 | 0.04 | 0.04 | 0.42 | 0.03 | 0.08 | Upgrade
|
| Cash Income Tax Paid | 38.58 | 38.58 | 53.72 | 43.59 | 66.68 | 43.77 | Upgrade
|
| Levered Free Cash Flow | -31.09 | 22.33 | 29.72 | 158.98 | -11.33 | -12.63 | Upgrade
|
| Unlevered Free Cash Flow | -31.02 | 22.46 | 29.78 | 159.06 | -7.03 | -8.43 | Upgrade
|
| Change in Working Capital | -60.64 | -60.64 | -82.93 | 88.32 | -81.62 | -104.59 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.